Kobayashi Pharmaceutical Co (KBYPF) Stock Statistics & Valuation Metrics

Kobayashi Pharmaceutical Co has a market cap or net worth of $2.78B. The enterprise value is ―.

Kobayashi Pharmaceutical Co has 78,050,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kobayashi Pharmaceutical Co’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 8.21%.

The current PE Ratio of Kobayashi Pharmaceutical Co is 46.00. Kobayashi Pharmaceutical Co’s PEG ratio is -37.49.

In the last 12 months, Kobayashi Pharmaceutical Co had revenue of 165.60B and earned 10.07B in profits. Earnings per share was 135.42.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Kobayashi Pharmaceutical Co pays an annual dividend of $0.306, resulting in a dividend yield of 1.75%

Kobayashi Pharmaceutical Co upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Kobayashi Pharmaceutical Co as a current ratio of 3.11, with Debt / Equity ratio of 0.40%

In the past 12 months, Kobayashi Pharmaceutical Co has paid 3.84B in taxes.

Kobayashi Pharmaceutical Co EV to EBITDA ratio is 12.62, with an EV/FCF ratio of -27.89.

Kobayashi Pharmaceutical Co has $65.75B in cash and marketable securities with ¥846.00M in debt, giving a net cash position of -$64.90B billion.

Gross margin is 52.47%, with operating margin of 15.01%, and net profit margin of 6.08%.

The average price target for Kobayashi Pharmaceutical Co is $35.56, which is 11.43% higher than the current price. The consensus rating is Hold